SCHEMBL2803450

SCHEMBL2803450

O=C(Nc1cccc(C(=O)N2CCCC(CO)C2)c1)N1CCc2c(cnc3[nH]ncc23)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK1 Q13153 3/20 0.42
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
NAMPT P43490 3/20 0.40
BTK Q06187 1/20 0.38
CCR2 P41597 3/20 0.38
KCNH2 Q12809 2/20 0.38
IRAK4 Q9NWZ3 1/20 0.38
LMNA P02545 1/20 0.38
EPHX2 P34913 1/20 0.38
NTRK1 P04629 1/20 0.37
CYP4F2 P78329 1/20 0.37
CYP4A11 Q02928 1/20 0.37
JAK2 O60674 1/20 0.37
VNN1 O95497 1/20 0.36
CCNK O75909 1/20 0.36
CDK12 Q9NYV4 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3R2 O00459 1/20 0.36
PIK3CA P42336 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2807727 0.91 PAK1 (0.46) PAK1NPC1RAB9ANAMPTIRAK4
SCHEMBL2802904 0.87 RAB9A (0.46) PAK1NPC1RAB9ANAMPTIRAK4
SCHEMBL2808230 0.87 PAK1 (0.46) PAK1NPC1RAB9ANAMPTNTRK1
SCHEMBL2804460 0.85 NAMPT (0.44) PAK1NPC1RAB9ANAMPTIRAK4
SCHEMBL2487747 0.84 NAMPT (0.50) PAK1NPC1RAB9ANAMPT
SCHEMBL2804038 0.84 ATR (0.45) PAK1NPC1RAB9ACCNKCDK12
SCHEMBL2487956 0.84 NPC1 (0.48) PAK1NPC1RAB9ANAMPTEPHX2
SCHEMBL2805025 0.84 NPC1 (0.42) PAK1NPC1RAB9ANAMPTIRAK4
SCHEMBL2806850 0.82 RAB9A (0.60) PAK1NPC1RAB9ALMNA
SCHEMBL2487737 0.82 NPC1 (0.49) PAK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 PAK1 717/4885NPC1 205/4885RAB9A 1240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.